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Adjuvant BEP (bleomycin, etoposide, cisplatin) is effective treatment for high-risk clinical stage I (HRCS1) non-seminomatous germ
cell tumours (NSGCT), but the known toxicities of etoposide, and the expansion of the HR group to any patient with vascular
invasion (50% of patients), led the Medical Research Council to pilot the BOP regimen. Patients received two courses of BOP 14 days
apart: cisplatin 50mgm
 2 days 1 and 2, vincristine 1.4mgm
 2 (max. 2mg) days 2 and 8, bleomycin 30000IU days 2 and 8. Primary
outcome was relapse rate; quality of life, fertility, hearing and lung function were assessed pre- and post-treatment. In all, 100 patients
were required. A total of 115 eligible patients were registered, all received two courses of chemotherapy. Median follow-up is 70
months; two relapses have occurred and the 5-year relapse-free rate is 98.3% (95% confidence interval (CI) 95.5%, 99.9%). As
assessed by clinicians during treatment, complete (reversible) alopecia was present in 20% of patients; World Health Organization
(WHO) grade 1/2 neurotoxicity was present in 41%/5% of patients during treatment and 22%/1% at 6 months. However, 12% of
patients reported ‘quite a bit’ or ‘very much’ pain/numbness/tingling in hands/feet 2 years after chemotherapy. Mature follow-up
confirms high efficacy for two courses of cisplatin-based adjuvant chemotherapy in HRCS1 NSGCT. Substituting vincristine for
etoposide decreases alopecia, but gives a low incidence of significant neuropathy. There are no clearcut advantages to 2 BOP over
2 BEP, except for patients who wish to maximise the chance of avoiding significant alopecia.
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Approximately 40% of men with non-seminomatous germ cell
tumours (NSGCT) of the testis present with stage I disease.
Surveillance has become a widely used initial management option
for these patients, following the successful treatment of dissemi-
nated germ cell tumours with cisplatin-based chemotherapy. Two
Medical Research Council (MRC) studies of surveillance (Freed-
man et al, 1987; Read et al, 1992) have shown that, overall,
approximately 25–30% of men with clinical stage I NSGCT
develop metastatic disease but that histopathological risk factors
(invasion of the testicular veins and/or lymphatics, absence of yolk
sac elements and presence of undifferentiated teratoma) could be
used to identify a high-risk group. Just over 20% of patients had
three or all four of these features, and their 2-year relapse-free rate
was 53%, compared with 83% in those with two or fewer risk
factors.
This risk was considered sufficiently high to warrant immediate
treatment, and the MRC TE05 trial (Cullen et al, 1996a) assessed
the value of two cycles of standard cytotoxic chemotherapy (BEP:
bleomycin, etoposide and cisplatin) in preventing recurrence. Data
published with a median follow-up of 4 years showed only one
relapse in the 103 patients with confirmed germ cell tumour on
review. These results suggested that it may be appropriate to offer
a broader range of patients adjuvant treatment.
Further analysis of the second MRC surveillance study (Read
et al, 1992) together with examination of the intra- and
interpathologist variation in identifying risk factors established
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sthat venous and lymphatic invasion were not always easily
distinguishable. However, the presence of either, irrespective of
other risk factors, conferred a risk of relapse of 35–40%.
Approximately 50% of stage I patients have vascular invasion
and, in view of the fact that around 60% of these ‘high-risk’
patients are not destined to relapse, the MRC Testis Tumour
Working Party considered whether there were alternative regimens
that might reduce the side effects associated with BEP. Although
these are relatively modest after two courses, side effects include
total alopecia, myelosuppression, reduced fertility and renal and
auditory dysfunction.
Etoposide is the drug principally responsible for alopecia and
myelosuppression, and possibly leukaemogenesis in a dose-related
manner. Therefore a logical step was to consider regimens without
etoposide. The present study evaluated the BOP regimen with
respect to short- and long-term toxicity and relapse rate.
Despite limited data on the efficacy of vincristine as a single
agent, schedules replacing etoposide by vincristine have been
shown to be effective (Merrin, 1980; Newlands et al, 1983;
Wettlaufer et al, 1984; Dearnaley, 1991; Lewis et al, 1991; Christian
et al, 2003). As BOP schedules are less myelosuppressive than BEP,
the treatment frequency can be increased and courses given at 1–2
week intervals, which may be advantageous in the treatment of
rapidly proliferating tumours (Dearnaley, 1991). The treatment
time of each cycle of adjuvant BOP was reduced to 48h, compared
to 3 days or more for BEP treatment, and the overall duration of
treatment reduced from 5 weeks with BEP to 3 weeks. Vincristine
at standard dose causes little if any alopecia and it was therefore
expected that the BOP regimen would not be associated with
significant alopecia.
The MRC therefore initiated a multicentre phase II pilot study of
two courses of adjuvant BOP, including assessment of toxicity,
relapse rate and quality of life (QoL). If this or a subsequent
regimen was shown to have a good toxicity profile, and no clear
evidence of inferior relapse rates was identified, a randomised trial
against the standard BEP could be considered.
PATIENTS AND METHODS
Eligibility
Patients had histologically confirmed NSGCT (included mixed
tumours) with high-risk features (tumour invasion of the testicular
lymphatics and or the testicular veins), and radiologically and
clinically confirmed stage I disease with normal tumour markers
(AFP, HCG) following orchidectomy and normal renal function
(creatinine clearance 475mlmin
 1). Patients were to be regis-
tered within 6–8 weeks of orchidectomy, or within 4 weeks of
postorchidectomy marker normalisation. Patients with elevated
markers, which did not fall at the rate expected from the marker
half-life were not eligible. The trial protocol was approved by each
participating centre’s research ethics committee, and all patients
gave informed consent to be in the trial.
Patients were registered on study, prior to commencing
chemotherapy, by a telephone call to the MRC Cancer Trials
Office, Cambridge UK (now the MRC Clinical Trials Unit, Cancer
Division).
Treatment
Within strict dose constraints, clinicians were able to employ the
schedule, fluid and antiemetic regimen with which they were most
familiar. Between days 1 and 2, 100mgm
 2 of cisplatin, 1.4mgm
 2
(max. 2mg) of vincristine and 30000IU of bleomycin were given.
The same doses of vincristine and bleomycin were repeated on day
8. The cycle was repeated on day 15 at full doses if the white cell
count (WCC) was X2.0 10
9l
 1, the platelet count was
X100 10
9l
 1 and either serum creatinine was o120mmoll
 1
or renal clearance 460mlmin
 1. If on day 15 the WBC
o2 10
9l
 1 or platelets o100 10
9l
 1, blood counts were
repeated daily until they exceeded these levels, at which time the
cycle started at full dose. If day 15 renal clearance was between 45
and 60mlmin
 1, 50% cisplatin dose was given; treatment at lower
renal clearance rates was on the advice of the clinical coordinator.
Postchemotherapy follow-up
Patients attended for follow-up at monthly intervals for the first
year, 2-monthly in the second year, three-monthly in the third year
and at 6-monthly intervals to 5 years. Subsequent follow-up was
according to usual centre practice. At each visit, a clinical
examination was performed, and blood taken for AFP and HCG.
Chest X-rays were performed at least every 2 months in the first
year, and chest and abdomen/pelvis CTs were performed at 6, 12
and 24 months from the start of chemotherapy. In the event of
recurrence, treatment was given according to the centres preferred
regimen for poor risk/recurrent metastatic teratoma.
Outcome measures
Relapse rate Time from start of chemotherapy to relapse, or date
last seen.
Acute toxicity Two weeks after cycle 2, clinicians reported the
maximum World Health Organization (WHO) grade of alopecia,
neurotoxicity, renal, mucosal and pulmonary toxicity and nausea/
vomiting since the start of chemotherapy. Alopecia was further
assessed at 2, 3 and 4 months after the start of chemotherapy, while
neurotoxicity was assessed at 3, 6, 12 and 24 months.
Long-term toxicity Prior to commencing chemotherapy sperm
analysis, hormone (LH, FSH, testosterone) analysis, audiometry
and pulmonary function tests were performed. These were
repeated at 12 months, and again at 2 years from the start of
chemotherapy.
Quality of life Health-related QoL was assessed through the use
of the EORTC core questionnaire (QLQ-C30) and the testicular
cancer module then under development (Fossa et al, 1996).
Patients were asked to complete the baseline questionnaires in the
clinic; the Trials Office then sent subsequent forms directly to the
patients’ homes, with pre-paid, preaddressed return envelopes,
approximately one week before the due completion dates of 4
weeks, 6 months, 12 months and 24 months after starting
chemotherapy.
Statistical considerations
In all, 100 patients were to be entered into the trial, enabling the
relapse rate to be estimated with an s.e. error o5%. As a relapse
rate of more than 5% would be considered unacceptable, the data
were monitored using an early termination scheme in which the
probability that the final relapse rate would exceed 5% was
calculated, conditional on the current data, at the time of each
relapse, as in our previous study (Cullen et al, 1996a).
Relapse-free rates were estimated using the Kaplan–Meier
method. Toxicity differences pre- and post-treatment were
compared using either the Wilcoxon test for matched pairs, or
the paired t-test if normality could be assumed.
The QLQ-C30 was scored according to the EORTC Scoring
Manual (EORTC, 1995). This identifies five functional scales
(physical, role, cognitive, social and emotional), one global health
scale, three multi-item symptom scales (fatigue, nausea and
vomiting, and pain), five individual symptom items (dyspnoea,
insomnia, appetite loss, constipation, and diarrhoea) and a
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squestion on financial difficulties. Each scale is standardised to
range in score from 0 to 100.
The testicular tumour questionnaire contains 20 questions
which were analysed individually. Only forms completed within
acceptable windows were used. Pretreatment forms had to be
completed on or before the day chemotherapy started; end-of-
treatment forms 4–8 weeks after the start of chemotherapy; 6-
month forms 5–7 months postchemotherapy, 12-month forms
10–14 months postchemotherapy and 24-month forms 22–26
months postchemotherapy.
The analysis focuses on descriptive statistics, but where formal
comparisons have been made of changes at specific time points
relative to baseline scores, an extreme level of statistical
significance (Po0.001) has been used to allow for the multiple
comparisons being performed. The formal tests of within-patient
changes from baseline used the Wilcoxon matched-pairs analysis.
RESULTS
Between August 1994 and July 1996, 116 patients were registered
from 16 centres in the UK and one in Norway. One patient who
was found to have raised markers on the day chemotherapy was
due to start was withdrawn and received instead three cycles of
BEP (he remains relapse-free 6 years after registration). The 115
remaining patients form the basis of this report.
Relapses
The median follow-up of relapse-free patients is 70 months. Two
confirmed relapses have occurred. One patient relapsed with a
2cm abdominal mass and negative markers 6 months after the
start of chemotherapy. He received two courses of VIP prior to
stem cell harvest and high-dose chemotherapy. He died from
toxicity 3 months after diagnosis of his relapse. The second patient
relapsed 3 months from the start of BOP with normal markers, a
3cm abdominal mass and a small (o1cm) lung mass. He received
POMB/ACE, but progressed before completing treatment. He went
on to further salvage including VIP (etoposide, ifosfamide and
cisplatin) and docetaxel, and is now alive and disease-free 5 years
after his first relapse was diagnosed. The 5-year relapse-free rate is
98.3% with 95% confidence interval (CI) (95.5%, 99.9%).
A third patient was suspected of having a relapse, with cerebral
metastases but negative markers and no other sign of disease, 26
months after BOP. He received chemotherapy (VIP) with no
impact on the brain CT appearances. Subsequent review and
biopsy indicates that the lesions seen were inflammatory. He
remains alive and free from any evidence of progression a further 2
years after the suspected relapse was seen.
Chemotherapy compliance
All patients received two cycles of chemotherapy. Eight patients
had intervals of more than 14 days between courses: two due to
administrative errors, two due to haematological toxicity, one
because of a sore throat and earache, and one due to tinnitus and
declining pulmonary function.
No dose reductions of cisplatin were necessary. Three patients
had dose reductions of vincristine in cycle 2 – one received none
because of abdominal pain, one received only one day because of
bleomycin-related toxicity (hyperpyrexia) and one had a 25%
reduction due to neuropathy.
Four patients had dose reductions of bleomycin – one received
only the first bleomycin dose of cycle 1 and none in cycle 2 because
of a skin rash, one received no bleomycin in cycle 2 because of
declining pulmonary function and two received only one dose in
cycle 2 – one because of abdominal pain (as above) and one
because of an unspecified bleomycin reaction.
Clinician-assessed acute toxicity
The clinicians’ assessment of toxicity at the end of chemotherapy is
given in Table 1. No WHO grade 3 or 4 haematological toxicity was
reported. Of 105 patients assessed at 6 months after the start of
chemotherapy neurotoxicity was absent in 81 (77%), grade 1 in 23
(22%) and grade 2 in 1 (1%). Of 75 patients assessed at 12 months,
67 (89%) had none and the remaining eight (11%) had only grade 1
neurotoxicity. At 4 months after starting chemotherapy, alopecia
was reported as absent or minimal in 79%, but still complete in
7%.
Long-term toxicity
Table 2 details the long-term toxicity data. Only patients with
pretreatment and follow-up assessments carried out at 1 year (73
months) after chemotherapy are included.
In all, 37 patients had complete audiometry data sets. The results
indicate a median 5dB hearing loss at 8kHz, which was
statistically significant (P¼0.008).
Between 22 and 29 patients (depending on the test performed)
had complete data sets on pulmonary function tests pre- and post-
treatment. There was no clear evidence of clinically relevant
changes, although the mean 5% reduction in KCO reached
conventional levels of statistical significance (P¼0.03).
In 61 patients with complete data on renal clearance, the mean
(s.d.) GFR fell from 124 (36)mlmin
 1 pretreatment to 113
(25)mlmin
 1 on follow-up. The estimated difference of 11 has a
95% CI (2–19%), P¼0.014.
In the 39 patients with semen analysis carried out pretreatment
and at 1 year, the median sperm density was 15 10
6ml
 1
(interquartile range (IQ) range 9–30) before chemotherapy with 11
patients (28%) having sperm densities of p10 10
6ml
 1. There
was no statistically significant change at 12 months, with the
median now 20 (IQ range 10–39), and 12 patients (31%) having
sperm densities of p10 ( 10
6ml
 1). LH, FSH and testosterone
were measured before chemotherapy and at 12 months in 34
patients. There were slight rises in both testosterone and
Table 1 Clinician-assessed toxicity, maximum WHO grades reported during chemotherapy
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Alopecia 19 18% 30 28% 36 34% 21 20% 0 —
Neurotoxicity 59 54% 45 41% 6 5% 0 — 0 —
Renal 103 96% 3 3% 0 — 1 1% 0 —
Mucosal 98 91% 6 6% 3 3% 1 1% 0 —
Pulmonary 96 90% 7 7% 4 4% 0 — 0 —
Nausea/vomiting 43 40% 33 31% 19 18% 12 11% 0 —
WBC
a 78 69% 28 25% 7 6% 0 — 0 —
Platelets
a 112 99% 0 — 1 1% 0 — 0 —
WHO¼World Health Organization; WBC¼White blood cells.
aBased on day 14 counts after each cycle.
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sgonadotrophin levels at 12 months, the increase being most
notable for FSH (median 7.8–9.0IUl
 1, Po0.001).
Quality of life
Of 115 eligible patients registered, 102 returned pretreatment
questionnaires, 90 of which were within the acceptable window.
Compliance with subsequent QoL forms is summarised in Table 3.
Core questionnaire (EORTC QLQ-C30)
Patterns of change are shown in Table 4 and Figures 1–3, which
show the mean score (translated to a 0–100 point scale) over all
patients for the functional scales (high score¼good result),
symptom scales (low score¼good result), and global health scales
(high score¼good result) respectively. The figures are based only
on patients completing the full set of pre- and post-treatment
questionnaires (n¼41). This represents approximately 46% of the
Table 2 Long-term toxicity
Test N
a Prechemo 1 year (7 3mths) postchemo P-value for change
b
Audiometry
Median loss at 2kHz (IQ range) 37 5dB (0–10) 5dB (0–10) 0.24
Median loss at 4kHz (IQ range) 38 10dB (5–15) 10dB (8–16) 0.24
Median loss at 8kHz (IQ range) 37 10dB (5–23) 15dB (10–30) 0.008
Pulmonary function tests
Mean KCO %predicted (s.d.) 23 102 (13) 97 (17) 0.03
Mean FEV %predicted (s.d.) 28 106 (13) 106 (11) 1.00
Mean FVC %predicted (s.d.) 29 110 (13) 109 (11) 0.43
Mean TLC %predicted (s.d.) 22 105 (13) 104 (14) 0.55
Hormones
Median LH (IQ range) 34 4.3 (3.6–6.7) 5.7 (4.2–7.5) 0.023
Median FSH (IQ range) 34 7.8 (5.9–9.1) 9.0 (6.9–11.4) o0.001
Median testosterone (IQ range) 30 14.3 (12.0–19.6) 16.7 (11.3–20.0) 0.57
KCO¼transfer coefficient for carbon monoxide; FEV¼forced expiratory volume; FVC¼forced vital capacity; TLC¼total lung capacity; LH¼luteinising hormone;
FSH¼follicle-stimulating hormone. IQ range¼interquartile range; s.d.¼standard deviation.
aNumber of patients with both baseline and follow-up values.
bPaired t-test for
pulmonary function test comparisons, Wilcoxon’s test elsewhere.
Table 3 Summary of compliance with quality of life questionnaires
Baseline
End of
chemo
6 Months
postchemo
12 Months
postchemo
24 Months
postchemo
Number of forms completed within window 90 87 83 78 73
Number (%) of patients with baseline and follow-up assessment completed within window 90 (100%) 69 (77%) 68 (76%) 66 (73%) 62 (69%)
Cumulative % of patients with full data up to this time point 90 (100%) 69 (77%) 58 (64%) 48 (53%) 41 (46%)
Table 4 Summary of QLQ-C30 subscale scores
Time point
QLQ-C30 subscales
(mean score) Pretreatment
End of
chemotherapy
6 Months
postchemo
12 Months
postchemo
24 Months
postchemo
Function scales
Physical 94 77 97 97 99
Role 88 69 94 95 96
Emotional 75 70 85 86 88
Cognitive 87 74 88 89 91
Social 78 54 89 96 90
Global health/Qol 76 49 78 78 82
Symptom scales
Fatigue 20 56 14 12 12
Nausea/vomiting 6 31 2 1 0.5
Pain 16 26 8 5 5
Dyspnoea 7 28 11 7 9
Insomnia 24 40 9 14 9
Appetite loss 9 45 6 7 5
Constipation 7 38 2 3 3
Diarrhoea 7 12 4 4 5
Financial difficulties 26 28 15 11 11
Qol¼quality of life.
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spatients with baseline scores, and in these circumstances, analysis
of ‘100% compliant’ patients may not be representative of the
group as a whole. However, the distribution of scores at specific
time points in this group of patients was compared with, and
found similar to, the distribution among all patients completing
that particular questionnaire.
All the subscales show the same trend, namely a significant
decline, relative to baseline, at the end of treatment, followed by
recovery, on average to baseline levels or better.
Testicular tumour questionnaire
In all, 85 patients completed the baseline questionnaire; 41 of these
patients also completed each of the subsequent forms up to and
including 24 months. Analysis has again focused on these ‘100%
compliant’ patients. Table 5 shows the percentage of patients
reporting ‘quite a bit’ or ‘very much’ to each of the questions on
the testis module at each of the time points. Comparisons of the
full range of scores at each time point relative to baseline have
been made using the Wilcoxon test for matched data.
Relative to baseline, all individual symptom items produced
worse scores at the end of treatment assessment, and those
significant at the adjusted significance level of o0.001 being hair
loss, pain, numbness or tingling in hands/feet and ringing in the
ears. Pain/numbness persisted at the same level of significance at 6
months post-treatment, reducing with time but remaining at the
conventional significance level of 5% at 24 months post-treatment.
Of the 41 patients completing the full set of questionnaires, five of
the 41 (12%) reported ‘quite a bit’ or ‘very much’ pain/numbness at
24 months and the percentage was similar if all 72 patients
completing this item of the 24 month questionnaire are considered,
irrespective of previous questionnaire compliance (8/72, 11%).
DISCUSSION
Adjuvant chemotherapy has become a standard of care for men
with high-risk stage I testicular teratoma in the UK using two
courses of BEP (RCR, 2000). Results of the previous MRC trial
TE05 (Cullen et al, 1996a) have been updated and with a median
follow-up of 7 years show no further recurrences, with one of 103
patients relapsing 6 months after adjuvant chemotherapy. This
man had rapidly progressive marker positive liver metastases and
died from his disease despite extensive salvage chemotherapy. The
5-year recurrence-free rate in TE05 among those confirmed with
germ cell tumours on central pathology review is 99.1% (95% CI
97.3%, 99.9%). Both recurrences in the present trial occurred
shortly after adjuvant chemotherapy (3 and 6 months) and both
patients received intensive further chemotherapy; one remains
alive and disease-free. The 5-year relapse-free rate is 98.3% (95.3,
99.9%). Although these results are barely distinguishable, it is
pertinent that the earlier MRC study was in a group of men with a
slightly higher expected risk of developing recurrent disease
(approximately 50% compared to 35–40% in the current report).
Similar efficacy has been reported for two courses of adjuvant
cisplatin-containing chemotherapy by other groups, although the
eligibility criteria vary and not all define an agreed ‘high-risk’
group. Pont et al (1996) have reported long-term results (median
follow-up 79 months) of their study of 29 patients with vascular
invasion who received two cycles of adjuvant BEP. One patient
relapsed 8 months after treatment and subsequently died from his
disease, and another developed a cystic lesion in the retro-
peritoneal nodes at 27 months; this was resected, found to contain
fully differentiated mature teratoma and the patient remains
relapse-free with no further treatment. Bohlen et al (1999) reported
mature results of a study in 58 patients who received two cycles of
BEP or PVB (cisplatin, vinblastine, bleomycin). The eligibility
criteria for this study defined a group at lower risk (one or more of
the risk factors: presence of embryonal carcinoma or vascular
invasion, or stage 4pT2). With a median follow-up of 93 months,
there have been no relapses demonstrating active disease, although
one patient again developed a mass in the iliac nodes which
contained only teratoma differentiated and was successfully
managed with surgery alone. Finally, Abratt et al (1994) treated
20 patients ‘at relatively high risk’ with two courses of adjuvant
BEP. With a median follow-up of 31 months, no relapses have been
reported.
An early fear with the adjuvant approach was that of acquired
chemoresistance, leading to poor outcome for those who do
relapse. In the literature summary above, six relapses have been
reported in 335 patients, and three of the relapsed patients died
from their germ cell tumour. These are limited data on which to
draw conclusions about acquired chemoresistance, but it would
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scertainly be difficult to improve on the crude cancer-specific
survival rate of 499%. It is also noteworthy that all three
recurrences in the MRC studies occurred within 6 months of
chemotherapy; this is an aggressive pattern of early relapse and
would be compatible with an hypothesis of primary rather than
acquired chemoresistance.
Since the present study was completed, results of a large
randomised MRC/EORTC trial in metastatic germ cell tumours
have been published (de Wit et al, 2001), establishing three courses
of BEP as standard management in good prognosis disease. This is
pertinent, as virtually all patients relapsing after postorchidectomy
surveillance will do so with good prognosis disease according to
the IGCCCG classification (IGCCCG, 1997). The total amount of
chemotherapy administered with a policy of adjuvant chemother-
apy (200 cycles per 100 high-risk patients) is now considerably
higher than a policy of surveillance, with three courses of
chemotherapy for the 40% expected to relapse (B120 cycles per
100 high-risk patients). This is clearly of some economic relevance,
but may be of less immediate relevance to the patient, given
evidence to suggest that the individual patient’s personality and
circumstances are the major factors determining whether or not
immediate prophylactic treatment is their preference (Cullen et al,
1996b). In addition, total amount of chemotherapy is not the only
consideration; a significant minority of patients relapsing on
surveillance will require retroperitoneal lymph node dissection
after chemotherapy. Even so, the trend towards less treatment for
metastatic disease gives further motivation to trials such as TE17,
aiming to maintain the efficacy of the adjuvant approach, while
reducing toxicity.
Although the dose intensity of cisplatin in the BOP schedule is
more than with BEP chemotherapy, the bleomycin dose is reduced
(30000IU  4 vs  6) and vinca alkaloids have lower efficacy than
etoposide (Williams et al, 1987). Nevertheless, the current study
has an estimated relapse rate at 5 years of 1.7%, and can exclude a
relapse rate of more than 5% with probability greater than 95%.
Toxicity of the BOP schedule is different from BEP chemother-
apy. Myelosupression is reduced, as judged by day 14 blood
counts. However, previous studies of adjuvant treatment have not
systematically attempted to record other short- and longer-term
toxicities of treatment and make direct comparison of the BOP and
BEP schedules difficult. The BOP schedule reduced the near 100%
alopecia rate seen with BEP; nevertheless, 59% of patients still
reported ‘quite a bit’ (46%) or ‘very much’ (13%) hair loss at the
end of treatment. However, only 17% of men with alopecia at the
end of treatment reported ‘quite a bit’ or ‘very much’ upset from
hair loss. Overall, these results suggest that alopecia is a fairly
minor consideration for men currently undergoing adjuvant
chemotherapy. This finding may in part depend on the hair
fashions current at the time of the study.
Perhaps of more concern is the persistent neuropathy noted as
‘pain, numbness and tingling in hands or feet’ which was recorded
as ‘quite a bit’ or ‘very much’ by 37% of men at the end of
treatment and 12% of men 2 years later. QoL data has not been
collected in any previous trials of adjuvant BEP.
3,13 15 We
therefore chose to compare the BOP data with those of patients
receiving three cycles of BEP within the MRC TE20/EORTC 30941
trial of chemotherapy for good prognosis metastatic disease (Fossa
et al, 2003). For direct comparison, these questionnaire items must
be transformed to a 0–100 scale, as for the core questionnaire. In
the present study, the mean scores are 41 at the end of treatment
and 16 after 2 years of treatment. These are slightly higher than the
corresponding figures after three courses of BEP, which were 27 at
the end of treatment and 12 after 2 years (with a similar level of
compliance with questionnaires). It would be expected that two
rather than three courses of BEP would produce less toxicity.
Although a nonrandomised comparison, these data strongly
suggest that BOP produces more neuropathy than BEP. Reduction
of vincristine dosage would be expected to improve tolerance but a
further assessment of treatment efficacy would then be required. If
undertaken, we consider that a randomised phase II comparison
with BEP would be most appropriate and EMG might usefully
complement QL or questionnaire-based assessment of peripheral
nerve function.
Some impact on high tone hearing loss was detected clinically,
this showed slight improvement during follow-up and was
paralleled by the testicular cancer module questionnaire responses
Table 5 Summary data from the testis tumour module
Testicular tumour module Pretreatment
End of
treatment
6 Months
posttreatment
12 Months
posttreatment
24 Months
posttreatment
Have you: % of patients reporting ‘quite a bit’ or ‘very much’
a
y lost any hair? 3% 59% 10% 0% 7%
If yes, been upset by your hair loss? 0% 17% 33% 0% 14%
y had pain, numbness of tingling in your hands and/or feet? 0 3% 37% 24% 13% 12%
y had pale/cold fingers/toes? 0% 15% 12% 7% 7%
y had ringing in the ears? 3% 37% 10% 7% 2%
y had difficulty hearing? 3% 5% 2% 7% 5%
y felt less masculine as a result of your disease or treatment? 5% 15% 7% 7% 5%
y had dry ejaculation during intercourse? 5% 3% 3% 0% 3%
y been interested in sex? 64% 27% 71% 78% 80%
b
y had difficulty in getting an erection? 5% 15% 2% 13% 5%
y had difficulty in keeping an erection 8% 15% 5% 10% 8%
y had problems with the intensity of your orgasm? 5% 8% 5% 8% 5%
y been sexually active? 41% 20% 54% 54% 58%
If yes, enjoyed sex? 83% 72% 92% 84% 86%
ybeen worried abut the possibility of being unable to father a child? 18% 13% 7%
b 10% 2%
y had a satisfying partner relationship? 89% 81% 95% 91% 89%
y feared recurrence of the disease? 32% 37% 29% 18% 20%
y felt that the right treatment decisions were made ? 97% 95% 100% 92% 98%
y felt satisfied with your clinic visits? 90% 95% 93% 97% 90%
y been limited in your hobbies or other leisure pursuits? 31% 51% 7% 3%
b 2%
b
aCells shaded black indicate that a formal comparison with baseline levels was significantly different at the Po0.001 level; cells shaded in grey indicate differences at the level
0.001oPo0.01.
bIndicates an improvement relative to baseline.
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son hearing loss and tinnitus, which reduced over time back to
baseline levels by 24 months. Other QoL indices remained stable or
improved with time. No significant changes in testosterone levels
or semen analysis were seen, but a slight rise in gonadotrophin
levels and a 9% fall in renal function was observed.
Overall the BOP schedule has been shown to be effective
adjuvant chemotherapy; however, there are no clearcut advantages
over the standard treatment using BEP schedule, except for
patients who wish to maximise the chance of avoiding significant
alopecia.
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Appendix A1
The trial Principal Investigator was Professor David Dearnaley,
Institute of Cancer Research and Royal Marsden Hospital, Surrey
UK. The trial was initiated by the MRC Testicular Tumour
Working Party (now the National Cancer Research Institute
Testicular Cancer Clinical Studies Group) and coordinated by
the MRC Clinical Trials Unit, Cancer Division (formerly the MRC
Cancer Trials Office, Cambridge); the trial statistician was Sally
Stenning and the senior clinical trial manager was Pat Cook. The
centres and clinicians taking part in the trial were as follows:
Norwegian Radium Hospital, Oslo, Norway (20 patients); SD
Fossa, N Aass
Beatson Oncology Centre, Glasgow, UK (14 patients); SB Kaye, C
Twelves, H Yosef
Birmingham Oncology Centre, Birmingham, UK (9 patients);
MH Cullen
Middlesex Hospital, London, UK (nine patients); SJ Harland
Nottingham City Hospital, Nottingham, UK (9 patients); MPJ
Sokal
Northern Centre for Cancer Treatment, Newcastle-upon-Tyne,
UK (nine patients); JT Roberts, H Lucraft, D Ritchie
Bristol Oncology Centre, Bristol, UK (eight patients); JD Graham
Royal South Hants Hospital, Southampton, UK (6 patients); GM
Mead
Addenbrookes Hospital, Cambridge, UK (six patients); MV
Williams
Leicester Royal Infirmary, Leicester, UK (six patients); FJ
Madden (retired)
Royal Marsden Hospital, Sutton, UK (four patients); DP
Dearnaley, A Horwich
Mount Vernon Hospital, Harrow, UK (four patients); GJS Rustin
Clatterbridge Oncology Centre, Liverpool, UK (three patients);
PI Clark
Guy’s Hospital, London, UK (three patients); PJ Harper
Western General Hospital, Edinburgh (two patients); GCW
Howard
Cookridge Hospital, Leeds, UK (one patient); WG Jones (retired)
St James University Hospital, Leeds, UK (one patient);
P Selby
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